Section Arrow
CTNM.NASDAQ
- Contineum Therapeutics
Quotes are at least 15-min delayed:2024/05/16 09:37 EDT
Last
 15.25
-0.06 (-0.39%)
Day High 
15.25 
Prev. Close
15.31 
1-M High
16.09 
Volume 
606 
Bid
15
Ask
15.48
Day Low
15.12 
Open
15.12 
1-M Low
13.27 
Market Cap 
384.75M 
Currency USD 
P/E 13.67 
%Yield
10-SMA 15.24 
20-SMA 15.48 
50-SMA -- 
52-W High 16.09 
52-W Low 13.27 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
1.12/-0.66
Enterprise Value
384.86M
Balance Sheet
Book Value Per Share
-2.70
Cash Flow
Cash Flow Yield
0.07
Income Statement
Total Revenue
50.00M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
JAGXJaguar Health0.26+0.0049+1.92%-- 
SCPXScorpius Holdings0.085+0.0073+9.40%-- 
NBYNovaBay Pharmaceuticals0.099-0.0055-5.26%-- 
DNAGinkgo Bioworks Holdings0.825-0.0141-1.68%-- 
NVAXNovavax12.35-0.55-4.26%-- 
Quotes are at least 15-min delayed:2024/05/16 09:37 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.